The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with DEBRA Chile has enrolled 18 patients to date, with no drug-related side effects observed among the first 8 participants who have completed treatment.…
Read More
Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology Founding investors include Militia Hill Ventures and University of Utah See more here
Read More